Lipigon is currently conducting a Phase II clinical trial for its drug candidate, Lipisense. A positive outcome could open several strategic pathways to advance the project toward commercialization. The change in CEO reflects the company’s heightened focus on business development, it states.

“We are very pleased to welcome Johan Liwing as our new CEO and are currently in discussions with his predecessor, Stefan K. Nilsson, to define his continuing central role in the company. Johan’s extensive experience in the life science industry and his proven ability to build strong relationships with commercial partners are invaluable to Lipigon at a time when there will be an increasing focus on business development,” says Lars Öhman, Chairman of the Board of Lipigon Pharmaceuticals.

Johan Liwing

Johan Liwing (b. 1974) holds a Master of Science in Engineering from KTH Royal Institute of Technology and is currently the CEO of the cancer diagnostics company Prosmedic Sweden. Previously, he served as CEO of XNK Therapeutics and held several leading roles within the Johnson & Johnson Group in Sweden and internationally.

Related article

Navigating the Financial Landscape: Bankruptcy

Four months after XNK Therapeutics, located in Huddinge, Sweden, declared bankruptcy, the clinical-stage biotechnology company’s building and physical assets were sold and the lease agreement transferred to BioLamina. 


“My primary responsibility as CEO of Lipigon is to ensure rapid progress in the Phase II study of Lipisense while also sharpening the company’s focus on business development to fully leverage a positive outcome from the study. There is an urgent need for more effective treatments for severely elevated blood lipids, and Lipisense has unique properties that could greatly improve patients’ quality of life,” says Johan Liwing, the incoming CEO of Lipigon Pharmaceuticals.